Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors
Novocure has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018.
“We are extremely pleased to welcome Jeri to our board of directors,” said Bill Doyle, Novocure’s Executive Chairman. “Her significant biopharmaceutical and medical device experience as well as her finance, strategy and leadership skills will be invaluable as we grow our glioblastoma (GBM) business and advance our proprietary cancer therapy to commercialize indications beyond GBM.”
Ms. Hilleman is Chief Financial Officer of Intersect ENT, a medical device company with commercial products for the treatment of chronic sinusitis. Prior to joining Intersect ENT, she was Chief Financial Officer of Amyris Inc., a multi-national, renewable products company based in California and Brazil, from January 2008 to June 2012. Ms. Hilleman was a member of the board of directors and chair of the audit committee at Xenoport Inc., a commercial biopharmaceutical company, from January 2004 to July 2018. She also served as Chief Financial Officer of Symyx Technologies, a research services, software and instrumentation company, Ocera, a biopharmaceutical company, and Cytel, an immunotherapy company. She is also a director of Minerva Neurosciences. Jeri holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.